Clinical Trial Update: Lurbinectedin in FET-Fused Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluates Lurbinectedin in FET-fused tumors such as Ewing sarcoma and desmoplastic small round cell tumor. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Undifferentiated Sarcoma

Drugs mentioned

• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1, Phase 2 | Status: RECRUITING